financetom
Business
financetom
/
Business
/
Crypto copycats: Dogecoin at centre of trademark battle
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crypto copycats: Dogecoin at centre of trademark battle
Sep 15, 2021 11:44 AM

Crypto lovers and many others are familiar with Dogecoin. More so after Elon Musk endorsed it on Twitter several times. Musk is also known as the ‘Dogefather’ in the crypto community for throwing his weight behind Dogecoin, which started as a meme currency.

While Dogecoin was once relegated to tech niches, the token’s meteoric rise has caught the attention of even those who have no knowledge of cryptocurrency.

And now, Dogecoin is embroiled in a trademark battle over its name.

First launched in 2013, based on the viral meme of a Shiba Inu dog named Doge, the token is up by 8,414.30 percent over the past year even though it is only at a third of its peak price that it achieved in May.

Also read: Cryptocurrency prices on September 14: Bitcoin, Ether, Dogecoin slip; Solana climbs 3%

What is the trademark battle about?

The Dogecoin Foundation, a non-profit organisation that was established in Colorado, Denver, by the original token’s creators, has now filed to trademark the name. While its creators Billy Markus and Jackson Palmer left the cryptocurrency space disillusioned, other members who participated in the token’s development are still part of the foundation.

The foundation’s claim on the Dogecoin trademark is not the only one. At least half a dozen papers have been filed with the US Patent and Trademark Office with applicants vying to own the Dogecoin brand.

The foundation had been defunct for years but was re-established in August to help the cryptocurrency with advocacy and support. The board even included Jared Birchall, a close associate and representative of tech billionaire Elon Musk, and Ethereum co-founder Vitalik Buterin.

Also read: This dogecoin investor refuses to sell despite losing $167,000 in one day; says “hold on to dear life”

“We are here to accelerate the development effort by supporting current Dogecoin Core and future Dogecoin Developers to work on a full-time basis through sponsorship, as well as providing a welcome landing for new contributors hoping to help with the project,” the foundation stated.

Who are in the race?

Many have questioned the move to trademark a brand after eight years of existence, with critics saying that the foundation was only re-established when Dogecoin rose to prominence, becoming one of the five largest cryptocurrencies.

Many have capitalised on the Dogecoin brand by keeping it alive while the original foundation was defunct. One such organisation is Cook Islands-based Moon Rabbit AngoZaibatsu LLC, which has also applied for the Dogecoin trademark.

"We’re not doing it with any malicious intent," said Angel Versitti, Founder of Moon Rabbit AngoZaibatsu. "We thought it was abandoned, we thought it desperately needed guidance. We’re not going to make a U-turn just because the big kid came back to the playground."

Others have also stated that the idea of trying to trademark something which itself is a copy is at best ironic. With many cryptocurrencies having most of their code open to users to look through for security, many tokens are borne out of modifications of existing technology.

Dogecoin was built off an altcoin called Luckycoin, which itself was made based on Litecoin, a large altcoin. But Litecoin also owes its origin to the first cryptocurrency Bitcoin, whose code it bored. Dogecoin’s name is also directly inspired by the Doge meme and Bitcoin’s name.

But lawyers and legal experts believe that Dogecoin Foundation has the upper hand in terms of claiming the trademark. With the brand name being in continuous use for the cryptocurrency, the foundation is likely to win the trademark even if it might take over a year to do so.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Xcel Energy Misses Q4 Estimates, Reaffirms FY25 EPS Guidance, Focuses On Grid Modernization
Xcel Energy Misses Q4 Estimates, Reaffirms FY25 EPS Guidance, Focuses On Grid Modernization
Feb 6, 2025
Xcel Energy Inc. ( XEL ) shares are trading lower on Thursday after the company reported fourth-quarter FY24 results. The company reported revenue of $3.12 billion, which missed the consensus of $3.77 billion. Adjusted EPS of 81 cents missed the consensus of 87 cents. For 2024, Xcel Energy ( XEL ) reported ongoing earnings per share of $3.50 vs. $3.35 in 2023....
Market Chatter: Shell, TotalEnergies Sign LNG Supply Deal With Egypt
Market Chatter: Shell, TotalEnergies Sign LNG Supply Deal With Egypt
Feb 6, 2025
12:08 PM EST, 02/06/2025 (MT Newswires) -- Shell (SHEL) and TotalEnergies (TTE) signed liquefied natural gas deals with Egypt worth about $3 billion to supply 60 cargoes to satisfy demand for 2025, Reuters reported Thursday, citing three trading sources. The country, which became a net natural gas importer last year, abandoned plans to supply Europe after a sharp drop in...
Bancfirst Insider Sold Shares Worth $602,906, According to a Recent SEC Filing
Bancfirst Insider Sold Shares Worth $602,906, According to a Recent SEC Filing
Feb 6, 2025
12:02 PM EST, 02/06/2025 (MT Newswires) -- F Ford Drummond, Director, on February 05, 2025, sold 5,000 shares in Bancfirst ( BANF ) for $602,906. Following the Form 4 filing with the SEC, Drummond has control over a total of 6,000 common shares of the company, with 6,000 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/760498/000159396825000171/xslF345X05/primary_01.xml Price: 122.16, Change: +0.13, Percent Change:...
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Feb 6, 2025
Kura Oncology, Inc ( KURA ). and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML). What Happened: The KOMET-001 trial achieved its primary endpoint of complete response (CR) plus CR with partial hematological recovery (CRh) and the primary endpoint was statistically significant. The benefit-risk profile for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved